fashion -WSS

fashion

author：explore 2025-09-29 13:30:51 - browse：356

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

H5N1 bird flu: what we're starting to learn about infection in cows

What will Novo Nordisk's VC do with its influx of cash?

CDC wastewater surveillance dashboard to track bird flu hotspots

Software glitch causes Tandem insulin pump to shutdown, FDA warns

H5N1 bird flu: what we're starting to learn about infection in cows

The stability of $0 premiums in Medicare Advantage

hotspot

fashion

entertainment

In Memoriam: Notable people who died in 2023

2023 Nobel Prize in Medicine goes to Karikó and Weissman

BioMarin wins approval for gene therapy to treat hemophilia A

Google says AlphaFold 3 can map a vast universe of biomolecules

In age of alternative facts, a scholarly course on calling out crap

The Karikó problem: Lessons for funding basic research

Psychedelics group wrestles with new pharma identity

Will an HIV vaccine ever be a reality?

Jerome Adams on the need for new antivirals for Covid

Study: Adult vaccinations pay for themselves in societal benefits

focus

How to improve immunocompromised access to mAb treatments

Readout LOUD podcast: What to know about H5N1 bird flu

Use wet bulb globe temperature, not heat index, to protect workers

What we owe ALS patients — and why one company fell short

The biotech scorecard for Q4: 16 stock

With Roe v Wade overturned, abortion providers work to adapt

knowledge

Wikipedia

entertainment

knowledge